Tranzyme Pharma and Norgine Complete Enrollment in First of Two Pivotal Phase 3 Trials of Ulimorelin

RESEARCH TRIANGLE PARK, N.C., Dec. 7, 2011 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM) and Norgine B.V. today announced completion of patient enrollment in ULISES 007, the first of two Phase 3 pivotal trials of ulimorelin for the acceleration of gastrointestinal (GI) recovery in patients undergoing partial bowel resection. There are an estimated 1 million patients in the U.S. at high risk each year for delayed GI recovery after surgery, including approximately 385,000 bowel resection surgeries.